Patents by Inventor Philip E. Hass

Philip E. Hass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20170073409
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: May 20, 2015
    Publication date: March 16, 2017
    Inventors: David P. ARNOTT, Austin L. GURNEY, Philip E. HASS, James M. LEE, Yan WU
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20170008942
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: July 22, 2016
    Publication date: January 12, 2017
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • ANTI-INTERLEUKIN-33 ANTIBODIES AND USES THEREOF
    Publication number: 20160168242
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
    Type: Application
    Filed: November 10, 2015
    Publication date: June 16, 2016
    Inventors: Philip E. HASS, Meredith HAZEN, Yi-Chun HSIAO, Rajita KHOSLA, Gerald R. NAKAMURA, Dhaya SESHASAYEE, Menno VAN LOOKEREN CAMPAGNE, Hongkang XI, Wenwu ZHAI, Jack BEVERS, III, Nancy CHIANG
  • Anti-Factor D Antibody Variants and Uses Thereof
    Publication number: 20160017052
    Abstract: The invention relates to anti-Factor D antibody variants, their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation.
    Type: Application
    Filed: April 30, 2015
    Publication date: January 21, 2016
    Applicant: GENENTECH, INC.
    Inventors: Robert F. Kelley, Menno van Lookeren Campagne, Justin M. Scheer, Philip E. Hass, Devin Tesar
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20140314711
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 23, 2014
    Applicant: Genentech, Inc.
    Inventors: JUSTIN SCHEER, WENJUN OUYANG, RICHARD VANDLEN, PHILIP E. HASS, ERIC GARY STEFANICH, GANESH A. KOLUMAM, XIAOTING WANG, JED ROSS, NICHOLAS VAN BRUGGEN, WYNE P. LEE
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20110318301
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: December 29, 2011
    Inventors: David P. Arnott, Austin L. Gumey, Philip E. Hass, James M. Lee, Yan Wu
  • IL-17A/F heterologous polypeptides and therapeutic uses thereof
    Publication number: 20080161540
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: December 10, 2007
    Publication date: July 3, 2008
    Inventors: David P. Arnott, Austin L. Gurney, Philip E. Hass, James M. Lee, Yan Wu
  • Methods of treating coagulapathic or thrombotic disorders
    Patent number: 7354585
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 8, 2008
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett
  • Human anti-factor IX/IXa antibodies
    Patent number: 7049411
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: May 23, 2006
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett
  • Human anti-factor IX/IXa antibodies
    Patent number: 6624295
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of-FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: September 23, 2003
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Brigitte Devaux, Dan L. Eaton, Philip E. Hass, J. Kevin Judice, Daniel Kirchhofer, Shelley Suggett